Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 201

1.

Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study.

Panichi V, Rosati A, Bigazzi R, Paoletti S, Mantuano E, Beati S, Marchetti V, Bernabini G, Grazi G, Rizza GM, Migliori M, Giusti R, Lippi A, Casani A, Barsotti G, Tetta C; RISCAVID Study Group.

Nephrol Dial Transplant. 2011 Aug;26(8):2641-8. doi: 10.1093/ndt/gfq802. Epub 2011 Feb 16.

2.

Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study.

Panichi V, Rizza GM, Paoletti S, Bigazzi R, Aloisi M, Barsotti G, Rindi P, Donati G, Antonelli A, Panicucci E, Tripepi G, Tetta C, Palla R; RISCAVID Study Group.

Nephrol Dial Transplant. 2008 Jul;23(7):2337-43. doi: 10.1093/ndt/gfm951. Epub 2008 Feb 27.

3.

Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.

Carrero JJ, Bárány P, Yilmaz MI, Qureshi AR, Sonmez A, Heimbürger O, Ozgurtas T, Yenicesu M, Lindholm B, Stenvinkel P.

Nephrol Dial Transplant. 2012 Feb;27(2):709-15. doi: 10.1093/ndt/gfr288. Epub 2011 May 26.

4.

Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients.

Rattanasompattikul M, Molnar MZ, Zaritsky JJ, Hatamizadeh P, Jing J, Norris KC, Kovesdy CP, Kalantar-Zadeh K.

Nephrol Dial Transplant. 2013 Jul;28(7):1936-45. doi: 10.1093/ndt/gfs368. Epub 2012 Oct 8.

5.

2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.

Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T.

Ther Apher Dial. 2010 Jun;14(3):240-75. doi: 10.1111/j.1744-9987.2010.00836.x.

PMID:
20609178
6.

Soluble CD40 ligand is predictive of combined cardiovascular morbidity and mortality in patients on haemodialysis at a relatively short-term follow-up.

Desideri G, Panichi V, Paoletti S, Grassi D, Bigazzi R, Beati S, Bernabini G, Rosati A, Ferri C, Taddei S, Ghiadoni L; RISCAVID investigators.

Nephrol Dial Transplant. 2011 Sep;26(9):2983-8. doi: 10.1093/ndt/gfq823. Epub 2011 Feb 8.

7.

Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients.

Minutolo R, Conte G, Cianciaruso B, Bellizzi V, Camocardi A, De Paola L, De Nicola L.

Nephrol Dial Transplant. 2012 Jul;27(7):2880-6. doi: 10.1093/ndt/gfs007. Epub 2012 Feb 8.

8.

Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients.

Rivara MB, Ikizler TA, Ellis CD, Mehrotra R, Himmelfarb J.

BMC Nephrol. 2015 Jun 5;16:79. doi: 10.1186/s12882-015-0074-9.

9.

Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival.

Snaedal S, Heimbürger O, Qureshi AR, Danielsson A, Wikström B, Fellström B, Fehrman-Ekholm I, Carrero JJ, Alvestrand A, Stenvinkel P, Bárány P.

Am J Kidney Dis. 2009 Jun;53(6):1024-33. doi: 10.1053/j.ajkd.2009.02.008. Epub 2009 Apr 25.

PMID:
19394732
10.

Postdialysis outcomes associated with consistent anemia treatment in predialysis patients with chronic kidney disease.

Wish JB, Nassar GM, Schulman K, del Aguila M, Provenzano R.

Clin Nephrol. 2008 Apr;69(4):251-9.

PMID:
18397699
11.

Causes and consequences of inflammation on anemia management in hemodialysis patients.

Chawla LS, Krishnan M.

Hemodial Int. 2009 Apr;13(2):222-34. doi: 10.1111/j.1542-4758.2009.00352.x. Review.

PMID:
19432697
12.

[Comorbidity, anemia and response to erythropoiesis stimulating agents in chronic hemodialysis].

Anaya S, Rivera F, Sánchez de la Nieta MD, Carreño A, Vozmediano C, Alcaide MP, Arambarri M, Nieto J, Caparrós G, Ferreras I.

Nefrologia. 2008;28(2):186-92. Spanish.

13.

Mortality in incident haemodialysis patients: time-dependent haemoglobin levels and erythropoiesis-stimulating agent dose are independent predictive factors in the ANSWER study.

Fort J, Cuevas X, García F, Pérez-García R, Lladós F, Lozano J, Martín-Malo A; ANSWER study.

Nephrol Dial Transplant. 2010 Aug;25(8):2702-10. doi: 10.1093/ndt/gfq073. Epub 2010 Feb 22.

14.

Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients.

van der Weerd NC, Grooteman MP, Bots ML, van den Dorpel MA, den Hoedt CH, Mazairac AH, Nubé MJ, Penne EL, Wetzels JF, Wiegerinck ET, Swinkels DW, Blankestijn PJ, Ter Wee PM; CONTRAST Investigators.

Nephrol Dial Transplant. 2013 Dec;28(12):3062-71. doi: 10.1093/ndt/gfs488. Epub 2012 Nov 11.

15.

A vitamin E-coated polysulfone membrane reduces serum levels of inflammatory markers and resistance to erythropoietin-stimulating agents in hemodialysis patients: results of a randomized cross-over multicenter trial.

Panichi V, Rosati A, Paoletti S, Ferrandello P, Migliori M, Beati S, Bernabini G, Daini R, Casani A, Angelini D, Parrini M, Rossi A, Petrone I, Barsotti G, Donadio C, Donati G, Grazi G, Manca Rizza G, Garosi G, Sansoni E, Braccagni B, Sidoti A, Boracelli D, Biagioli M, Moriconi L, Finato V, Mannarino A, Grimaldi C, Pansa F, Imperiali P, Mura C, Bianchi S, Bigazzi R.

Blood Purif. 2011;32(1):7-14. doi: 10.1159/000321369. Epub 2011 Jan 14.

PMID:
21242686
16.

Oxidative stress, inflammation and cardiovascular mortality in haemodialysis--role of seniority and intravenous ferrotherapy: analysis at 4 years of follow-up.

Bayés B, Pastor MC, Bonal J, Foraster A, Romero R.

Nephrol Dial Transplant. 2006 Apr;21(4):984-90. Epub 2005 Dec 2.

17.
18.
19.

Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan.

Fukuma S, Yamaguchi T, Hashimoto S, Nakai S, Iseki K, Tsubakihara Y, Fukuhara S.

Am J Kidney Dis. 2012 Jan;59(1):108-16. doi: 10.1053/j.ajkd.2011.07.014. Epub 2011 Sep 3.

PMID:
21890255
20.

Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients.

Bradbury BD, Critchlow CW, Weir MR, Stewart R, Krishnan M, Hakim RH.

Nephrol Dial Transplant. 2009 Mar;24(3):919-25. doi: 10.1093/ndt/gfn543. Epub 2008 Oct 7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk